Status:
COMPLETED
Study of Escitalopram in the Treatment of Specific Phobia
Lead Sponsor:
Connor, Kathryn M., M.D.
Collaborating Sponsors:
Forest Laboratories
Conditions:
Phobic Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.
Detailed Description
This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypoth...
Eligibility Criteria
Inclusion
- Adults 18-65 years of age
- DSM-IV criteria for specific phobia according to the MINI
- For women of childbearing potential, a negative serum pregnancy test at screening
- Written informed consent
Exclusion
- Any current primary DSM-IV diagnosis other than specific phobia
- History of DSM-IV substance abuse or dependence within the last months
- Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
- Suicide risk or serious suicide attempt within the last year
- Clinically significant laboratory or EKG abnormality or unstable medical condition
- For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
- Subjects needing concurrent use of psychotropic medications
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00121069
Start Date
September 1 2002
End Date
September 1 2004
Last Update
July 21 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center
Durham, North Carolina, United States, 27710